Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Pancreatic Diseases 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Diseases 1Breast Neoplasms 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

darolutamide 3enzalutamide 2Pluvicto 2talazoparib 1olaparib 1gedatolisib 1apalutamide 1Standard of Care 1Radiotherapy 1Prednisone 1Lutetium-177 1Lutetium 1Docetaxel 1Androgen Antagonists 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostatic Diseases × Lutetium × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡